key: cord-0048454-xq50147i
authors: Wiseman, David M.
title: Re: Arshad S, Kilgore P, Chaudhry ZS et al. Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19. Int J Infect Dis: 2020. Epub 2020 Jul 1 http://doi.org/10.1016/j.ijid.2020.06.099
date: 2020-08-05
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.07.064
sha: 37a976f1156c189ff4db752abf284f5c4f081aaa
doc_id: 48454
cord_uid: xq50147i

nan

Letter to the editor, International Journal of Infectious Diseases Re: Arshad S, Kilgore P, Chaudhry ZS et al. Treatment with Hydroxychloroquine, Azithromycin, and Combination As its accompanying editorial (Lee et al., 2020) perceives, Arshad's report (Arshad et al., 2020) indeed fuels the fire of the hydroxychloroquine (HCQ) controversy. It also fans the steroid controversy (Salton et al., 2020) .

The 2541 consecutive COVID-19 subjects included over seven weeks from 3/10/20 undoubtedly included 213 consecutive patients, starting 3/12/20 for two weeks, in a pre/post quasi-experiment (Fadel et al., 2020 ). Fadel's conclusion that "early short course of methylprednisolone [MPD] in … moderate to severe COVID-19 … improved clinical outcomes" undoubtedly informed treatment protocols for the remaining five weeks of Arshad, affirming the editorial speculation that as Henry Ford Hospital System "became more experienced …, survival may have improved…" With differences in steroid use noted in the editorial, a comparison with Fadel (Table) is intriguing: -Sadr et al., 2020) ) found steroid-associated reduced mortality, but only after multivariate adjustment. These studies support the early combined in-hospital use of HCQ and MPD to reduce mortality and need for ventilation. This contrasts with an effect of dexamethasone limited to more advanced disease (Horby et al., 2020) possibly reflecting between-steroid pharmacological differences (Draghici et al., 2020) . Early use of MPD is supported by other studies, some of which (Salton et al., 2020) also involve HCQ with possible synergy via a lysosomal mechanism (He et al., 2011) . HCQ given alone at this stage, may require zinc (Carlucci et al., 2020) . In Arshad's less sick and comorbid (propensity matched) patients, HCQ's steroid requirement appears reduced. For early post-exposure prophylaxis in young subjects ((Boulware et al., 2020) , supplement), HCQ requires neither zinc nor steroid.

These data support prospective evaluation of a stage-and age-nuanced approach to COVID-19 that exploits the multiple mechanisms of HCQ and a synergy with MPD. Detailed stratification of observational studies involving HCQ, steroids (and heparin) is urged as well as the conduct of prospective meta-analyses of ongoing studies to facilitate meaningful sub-group analysis. 

Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19

Corticosteroid therapy for patients with CoVID-19 pneumonia: a before-after study

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients

COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases

Early Short Course Corticosteroids in Hospitalized Patients with COVID-19

Identification of a lysosomal pathway that modulates glucocorticoid signaling and the inflammatory response

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report

An Observational Cohort Study of Hydroxychloroquine and Azithromycin for COVID-19: (Can't Get No) Satisfaction

Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia